Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC
Public ClinicalTrials.gov record NCT03567720. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Multi-Cohort, Open-Label Study of Intratumoral Tavokinogene Telseplasmid Plus Electroporation in Combination With Pembrolizumab +/- Chemotherapy in Patients With Inoperable Locally Advanced/Metastatic Triple-Negative Breast Cancer
Study identification
- NCT ID
- NCT03567720
- Recruitment status
- Not listed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- OncoSec Medical Incorporated
- Industry
- Enrollment
- 65 participants
Conditions and interventions
Conditions
Interventions
- tavokinogene telseplasmid Biological
- Pembrolizumab Biological
- Immunopulse Device
- nab paclitaxel Drug
- gemcitabine plus carboplatin Drug
Biological · Device · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 10, 2018
- Primary completion
- Mar 31, 2024
- Completion
- Aug 31, 2024
- Last update posted
- May 31, 2023
2018 – 2024
United States locations
- U.S. sites
- 10
- U.S. states
- 8
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Arizona | Tucson | Arizona | 85719 | — |
| UC San Diego | La Jolla | California | 92093 | — |
| Stanford University Medical Center | Palo Alto | California | 94304 | — |
| The Lundquist Institute | Torrance | California | 90502 | — |
| University of Colorado Cancer Center | Aurora | Colorado | 80045 | — |
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| University of Chicago | Chicago | Illinois | 60637 | — |
| University Hospitals Seidman Cancer Center | Cleveland | Ohio | 44106 | — |
| Virginia Cancer Specialists | Fairfax | Virginia | 22031 | — |
| University of Washington, Seattle Cancer Care Alliance | Seattle | Washington | 98195 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03567720, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 31, 2023 · Synced Jul 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03567720 live on ClinicalTrials.gov.